SCHEMBL1871002

SCHEMBL1871002

COc1ccc(-c2ccc(C(=O)O)s2)cn1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.65
ALDH1A1 P00352 4/20 0.65
GAA P10253 3/20 0.65
POLB P06746 2/20 0.55
RAB9A P51151 2/20 0.55
NPC1 O15118 2/20 0.55
GLA P06280 2/20 0.55
SMN1; SMN2 Q16637 2/20 0.55
IKBKE Q14164 1/20 0.53
TBK1 Q9UHD2 1/20 0.53
MEN1 O00255 1/20 0.53
KMT2A Q03164 1/20 0.53
MKNK1 Q9BUB5 2/20 0.51
MKNK2 Q9HBH9 2/20 0.51
NR4A2 P43354 1/20 0.48
ERN1 O75460 1/20 0.47
CYP2A6 P11509 2/20 0.47
MAP3K8 P41279 1/20 0.46
TOP1 P11387 1/20 0.45
HPGD P15428 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6260309 0.83 ALDH1A1 (0.62) KDM4EALDH1A1GAAPOLBRAB9A
SCHEMBL3088695 0.83 HDAC6 (0.59) KDM4EALDH1A1GAAMKNK1MKNK2
SCHEMBL23091163 0.82 KDM4E (0.49) KDM4EALDH1A1GAARAB9ANPC1
SCHEMBL20894161 0.81 MKNK1 (0.49) ALDH1A1RAB9ANPC1SMN1; SMN2MKNK1
SCHEMBL12922044 0.80 KDM4E (0.71) KDM4EALDH1A1GAAPOLBRAB9A
SCHEMBL17201571 0.79 ALDH1A1 (0.52) KDM4EALDH1A1GAAPOLBRAB9A
SCHEMBL6260316 0.79 KDM4E (0.50) KDM4EALDH1A1GAAPOLBRAB9A
SCHEMBL6259708 0.79 KDM4E (1.00) KDM4EALDH1A1GAAPOLBRAB9A
SCHEMBL17201506 0.78 KDM4E (0.47) KDM4EALDH1A1GAAPOLBRAB9A
SCHEMBL2544746 0.78 KDM4E (0.69) KDM4EALDH1A1GAAPOLBRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7947684-B2 anticoagulants; immunomoderators; antiinflammatory agents AVENTIS PHARMACEUTICALS INC. (US) 2011-05-24 US disclosed
US-20040220171-A1 1-Aroyl-piperidinyl benzamidines AVENTIS PHARMACEUTICALS INC 2004-11-04 US disclosed
EP-1278732-A1 1-AROYL-PIPERIDINYL BENZAMIDINES Aventis Pharmaceuticals Inc. (US) 2003-01-29 EP disclosed
US-20020045613-A1 1-aroyl-piperidinyl benzamidines AVENTIS PHARMACEUTICALS PRODUCTS INC. 2002-04-18 US disclosed
WO-2001081310-A1 1-AROYL-PIPERIDINYL BENZAMIDINES AVENTIS PHARMACEUTICALS INC. (US) 2001-11-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040220171-A1 1-Aroyl-piperidinyl benzamidines TPSAB1, TPSB2, CMA1 KDM4E 2191/4885ALDH1A1 567/4885GAA 97/4885
US-20020045613-A1 1-aroyl-piperidinyl benzamidines TPSAB1, TPSB2, CMA1 KDM4E 2191/4885ALDH1A1 567/4885GAA 97/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.